@OhioStateNeph @JasonProsek and Eshetu Obole
PLEX or daratumumab for myeloma cast nephropathy? A 549-patient target trial emulation found neither linked to better kidney recovery at 90 days. Glimmer of hope or mirage?View quoted post on X
⬇️New #NephJC Short by @brian_rifkin
nephjc.com/news/daravsple…